# EDGAR Filing Document

**Accession Number:** 0001069530
**File Stem:** 0001562762-23-000120
**Filing Date:** 2023-3
**Character Count:** 5532
**Document Hash:** a1ca79f60db4568c458c999a169bbe53
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001562762-23-000120.hdr.sgml**: 20230317

**ACCESSION NUMBER**: 0001562762-23-000120

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 12

**CONFORMED PERIOD OF REPORT**: 20230316

**ITEM INFORMATION**: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230317

**DATE AS OF CHANGE**: 20230316

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** CASSAVA SCIENCES INC
- **CENTRAL INDEX KEY:** 0001069530
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 911911336
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-29959
- **FILM NUMBER:** 23739988

**BUSINESS ADDRESS:**
- **STREET 1:** 6801 N CAPITAL OF TEXAS HIGHWAY
- **STREET 2:** BUILDING 1; SUITE 300
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78731
- **BUSINESS PHONE:** 512-501-2444

**MAIL ADDRESS:**
- **STREET 1:** 6801 N CAPITAL OF TEXAS HIGHWAY
- **STREET 2:** BUILDING 1; SUITE 300
- **CITY:** AUSTIN
- **STATE:** TX
- **ZIP:** 78731

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PAIN THERAPEUTICS INC
- **DATE OF NAME CHANGE:** 20000309

?xml version="1.0" encoding="utf-8"? sava-20230316x8k

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

___________________

**FORM 8-K**

___________________

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported) March 16, 2023**

___________________

## Cassava Sciences, Inc.
**(Exact name of registrant as specified in its charter)**

___________________

---

| | | |
|:---|:---|:---|
| **Delaware**  | **000-29959**  | **91-1911336**  |
| **(State or other jurisdiction**<br>**of incorporation)** | **(Commission**<br>**File Number)** | **(I.R.S. Employer**<br>**Identification Number)** |

---

**6801 N Capital of Texas Highway, Building 1; Suite 300**

**Austin, Texas 78731**

**(Address of principal executive offices, including zip code)**

**(512) 501-2444**

**(Registrant's telephone number, including area code)**

**(Former name or former address, if changed since last report.)**

___________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

---

| |
|:---|
| ThereWritten communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17CFR 240.14d-2(b)) |
| Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17CFR 240.13e-4(c)) |

---

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading**<br>**Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, $0.001 par value  | SAVA  | NASDAQ Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 **‎** 

------

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.** 

Effective on March 16, 2023, the Board of Directors of Cassava Sciences, Inc. (the "Board") amended the Cassava Sciences, Inc. 2020 Cash Incentive Bonus Plan (the "Cash Incentive Plan") to remove all of the Board's non-employee directors (the "Non-employee Directors) as beneficiaries under the Cash Incentive Plan and the Non-employee Directors consented to such removal. The Non-employee Directors' share of potential benefits under the Cash Incentive Plan were completely forfeited to Cassava Sciences, Inc. and will not be allocated to any other participant under the Cash Incentive Plan. The Non-employee Directors have not received, and as a result of such amendment will never receive, any payments under the Cash Incentive Plan.

**Item 9.01. Financial Statements and Exhibits.**

---

| | |
|:---|:---|
| **<u>Exhibit Number</u>** | **<u>Description</u>** |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

‎

------

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **CASSAVA SCIENCES, INC.** | **CASSAVA SCIENCES, INC.** |
|  | a Delaware corporation | a Delaware corporation |
| Date: March 16, 2023 |  |  |
|  | By: | <u>/s/ ERIC J. SCHOEN</u> |
|  |  | Eric J. Schoen |
|  |  | Chief Financial Officer |

---